English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

© Translational Andrology and Urology. All rights reserved. Bladder cancer caused an estimated 17,980 deaths in the United States in 2020 (1). Unfortunately, death from bladder cancer has not decreased over the last few decades, with an estimated 12,200 deaths in 2000, a trend corroborated by independent analysis (2,3). Over the past years we have witnessed an explosion of advances in bladder cancer treatment, spanning from novel bladdersparing treatments for non-muscle invasive disease to the development and rapid adoption of immune checkpoint inhibition for advanced stages (4,5). How do we harness these advances to move the needle and improve oncologic outcomes for bladder cancer? One facet will be to contextualize all advances across specialties rather than viewing them in isolation from a single standpoint. Advances in the management of non-muscle invasive disease, trimodal therapy, and immune checkpoint inhibition should not be relegated exclusively to the domains of urologists, radiation oncologists, and medical oncologists, respectively. To improve outcomes for patients with bladder cancer, inclusive multi-specialty collaboration is required to synthesize a succinct and centralized best practice resource. The recent EAU-ESMO Consensus statements by Witjes et al. on the management of advanced and variant bladder cancer is a colossal and timely international multi-specialty effort (6). The authors utilized Delphi methodology to draw from 134 experts from 23 countries, comprised of urologists, oncologists (including medical and radiation oncologists), and “other” stakeholders (including radiologists, pathologists, specialist nurses, clinical oncologists, and nuclear medicine specialists). While the entirety of the 143 consensus statements warrant careful review, several statements are of particular interest and importance across the landscape of bladder cancer.

Consensus statements from the EAU-ESMO collaboration for advanced and variant bladder cancer: can we move the needle to improve survival?